taipugrel

Taipugrel is a novel, orally active small molecule P2Y12 receptor antagonist developed by the Tianjin Institute of Pharmaceutical Research. It belongs to the thienopyridine class of antiplatelet agents, which includes drugs like clopidogrel and prasugrel. Taipugrel acts as a prodrug that requires metabolic activation to inhibit the P2Y12 subtype of adenosine diphosphate (ADP) receptors on the surface of platelets. By blocking these receptors, it prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet aggregation and reducing the risk of thrombus formation. The drug is primarily being developed for the treatment of acute coronary syndrome (ACS) and the prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI), with the goal of providing more rapid and potent platelet inhibition than first-generation thienopyridines.

Brand names

tiprogrel

Other names

taipugrel hydrochloride泰普格雷